Clinical trial
Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus…
NCT00362635 · Bukwang Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00362635 |
|---|---|
| Title | Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection |
| Official title | A Double-blinded and Randomised Study to Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30 mg qd Versus Lamivudine 100 mg qd for Chronic Hepatitis B Infection |
| Lead sponsor | Bukwang Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hepatitis B |
| Intervention type | Drug |
| Interventions | Clevudine |
| Enrollment | 92 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2011 |
| First posted | Aug 10, 2006 |
| Last update posted | Jul 26, 2012 |
| Countries | Hong Kong |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: